Proteomics beyond proteomics: Toward clinical applications

Current Opinion in Oncology

Volumn 23, Issue 1, 2011, Pages 77-82

  Plymoth, Amelie ^a,b   Hainaut, Pierre ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Bioinformatics; Biomarkers; Clinical proteomics; Mass spectrometry; Proteomics

Indexed keywords

BIOLOGICAL MARKER; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; TUMOR MARKER;

ARTICLE; FOOD AND DRUG ADMINISTRATION; GENE SEQUENCE; HUMAN; MASS SPECTROMETRY; MEDICAL RESEARCH; MULTIPLE REACTION MONITORING MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 79851513271     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834179c1     Document Type: Article

References (32)

1. The Human Proteome organization. A gene-centric human proteome project: HUPO-the Human Proteome organization. Mol Cell Proteomics 2010; 9:427-429.
2. Gygi SP, Rochon Y, Franza BR, et al. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999; 19:1720-1730. (Pubitemid 29098230)
3. Cox J, Mann M. Is proteomics the new genomics? Cell 2007; 130:395-398. (Pubitemid 47198310)
4. Pitteri S, Hanash S. A systems approach to the proteomic identification of novel cancer biomarkers. Dis Markers 2010; 28:233-239.
5. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008; 3:571-579. (Pubitemid 351483371)
6. Dunn MJ. PROTEOMICS: ten years in the field. Proteomics 2010; 10: • 1-3.
7. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003; 422:198-207. (Pubitemid 36362757)
8. Washburn MP, Wolters D, Yates JR. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotech-nol 2001; 19:242-247. (Pubitemid 32220565)
9. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1:845-867.
10. Picotti P, Rinner O, Stallmach R, et al. High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat Methods 2010; 7:43-46.
11. Anderson NL. Libraries of specific assays covering whole proteomes: from yeast to man. Clin Chem 2010; 56:1521-1522.
12. Hanash S, Taguchi A. The grand challenge to decipher the cancer proteome. Nat Rev Cancer 2010; 10:652-660.
13. Celis JE, Moreira JM. Clinical proteomics. Mol Cell Proteomics 2008; 7:1779.
14. Ornstein DK, Rayford W, Fusaro VA, et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol 2004; 172:1302-1305. (Pubitemid 39249702)
15. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006; 116:271-284. (Pubitemid 43121812)
16. Liu XP, Shen J, Li ZF, et al. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry. Cancer Invest 2006; 24:747-753. (Pubitemid 44949879)
17. Belluco C, Petricoin EF, Mammano E, et al. Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann Surg Oncol 2007; 14:2470-2476. (Pubitemid 47389555)
18. Patz EF Jr, Campa MJ, Gottlin EB, et al. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 2007; 25:5578-5583.
19. Hortin GL. The MALDI-TOF massspectrometric viewoftheplasmaproteome and peptidome. Clin Chem 2006; 52:1223-1237.
20. Hortin GL, Carr SA, Anderson NL. Introduction: advances in protein analysis for the clinical laboratory. Clin Chem 2010; 56:149-151.
21. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010; 56:177-185.
22. Fehniger TE, Marko-Varga G. Proteomics and disease revisited: the challenge of providing proteomic tools into clinical practice. J Proteome Res 2010; 5:1191-1192.
23. Andersen JN, Sathyanarayanan S, Di Bacco A, et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Trans Med 2010; 4:43ra55.
24. Mann M, Kelleher NL. Precision proteomics: the case for high resolution and high mass accuracy. Proc Natl Acad Sci U S A 2008; 105:18132-18138.
25. Hortin GL. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin Chem 2005; 51:3-5. (Pubitemid 40024002)
26. US Food and Drug Administration. FDA clears a test for ovarian cancer. Test can help identify potential malignancies, guide surgical decisions. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm182057.htm. [Accessed October 2010]
27. Nilsson T, Mann M, Aebersold R, et al. Mass spectrometry in high-throughput proteomics: ready for the big time. Nat Methods 2010; 7:681-685.
28. Burlingame AL, Stults JT. Mass spectrometry and the evolution of proteomics. Mol Cell Proteomics 2010; 9:753.
29. Hoofnagel AN, Becker JO, Wener MH, et al. Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem 2008; 54:1796-1804.
30. Picotti P, Bodenmiller B, Mueller LN, et al. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell 2009; 21:795-806.
31. Martens L, Chambers M, Sturm M, et al. mzML: a community standard for mass spectrometry data. Mol Cell Proteomics 2010. [Epub ahead of print]
32. Vizcaíno JA, Cǒté R, Reisinger F, et al. The PRoteomics IDEntifications database: 2010 update. Nucleic Acids Res 2010; 38:D736-D742.